原发性脑出血:深入探讨高血压与脑淀粉样血管病
该前瞻性队列研究于2009至2015年纳入原发性脑出血患者,用改良Boston标准识别 probable/definite 和 possible 脑淀粉样血管病相关脑出血(CAA-ICH),用SMASH-U标准识别高血压 ICH,排除药物及系统性凝血病所致 ICH。共识别204例高血压 ICH、55例 probable/definite CAA-ICH 和46例 possible CAA-ICH。校正女性、ICH评分组分及EVD放置后,probable/definite CAA-ICH 较高血压 ICH 院内死亡率更低(OR 0.2;95%CI 0.05-0.8;p=0.02),possible CAA-ICH 与高血压 ICH 无死亡率差异,probable/definite 较 possible CAA-ICH 院内死亡率更低(OR 0.2;95%CI 0.04-0.7;p=0.02)。以 ICH 病因为预测变量的死亡模型优于以血肿部位为预测变量(χ2 [df=2, N=305]=6.2;p=0.01)。作者结论为需进一步研究确认所观察到的死亡率异质性,仅按血肿部位分类可能低估病因异质性。
要点
- 校正女性、ICH评分组分及EVD放置后,probable/definite CAA-ICH 较高血压 ICH 院内死亡率更低(OR 0.2;95%CI 0.05-0.8;p=0.02)。
- possible CAA-ICH 与高血压 ICH 之间院内死亡率无差异。
- probable/definite CAA-ICH 较 possible CAA-ICH 院内死亡率更低(OR 0.2;95%CI 0.04-0.7;p=0.02)。
- 以 ICH 病因为预测变量的院内死亡模型显著优于以血肿部位为预测变量的模型(χ2 [df=2, N=305]=6.2;p=0.01)。
- 该队列中 probable/definite CAA-ICH 患者年龄更大、血肿体积更大,但院内死亡率仍低于高血压 ICH。
适用人群与场景
- 2009至2015年前瞻性收集的原发性、自发性脑出血患者。
- 排除药物及系统性疾病所致凝血病性 ICH。
诊断标准与关键阈值
- 采用改良Boston标准识别 probable/definite CAA-ICH 与 possible CAA-ICH,两者分别评估。
- 采用SMASH-U标准识别高血压 ICH。
研究设计与关键结果
- 研究类型为前瞻性队列,共纳入204例高血压 ICH、55例 probable/definite CAA-ICH 和46例 possible CAA-ICH。
- 校正女性、ICH评分组分及EVD放置后,probable/definite CAA-ICH 较高血压 ICH 院内死亡率更低(OR 0.2;95%CI 0.05-0.8;p=0.02)。
- possible CAA-ICH 与高血压 ICH 之间院内死亡率无差异。
- probable/definite CAA-ICH 较 possible CAA-ICH 院内死亡率更低(OR 0.2;95%CI 0.04-0.7;p=0.02)。
- 以 ICH 病因为预测变量的院内死亡模型较以血肿部位为预测变量的模型显著改善(χ2 [df=2, N=305]=6.2;p=0.01)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 作者结论:需进一步研究确认本原发性 ICH 队列中观察到的死亡率异质性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,仅按血肿部位分类可能遗漏原发性 ICH 的病因异质性,尤其在大叶性 ICH 中 competing 病因可能并存。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/PURPOSE: Primary intracerebral hemorrhage (ICH) studies often use hematoma location rather than ICH etiologies when assessing outcome. Characterizing ICH using hematoma location is effective/reproducible, but may miss heterogeneity among these ICH locations, particularly lobar ICH where competing primary ICH etiologies are possible. We subsequently investigated baseline characteristics/outcome differences of spontaneous, primary ICH by their etiologies: cerebral amyloid angiopathy (CAA) and hypertension.
METHODS: Primary ICH clinical/outcomes data were prospectively collected between 2009 and 2015. Modified Boston criteria were used to identify "probable/definite" and "possible" CAA-ICH, which were evaluated separately. SMASH-U criteria were used to identify hypertension ICH. Medication and systemic disease coagulopathy ICH were excluded. Baseline characteristics/outcomes among "probable/definite" CAA-ICH, "possible" CAA-ICH, and hypertension ICH were compared using logistic regression. Mortality models using ICH etiologies compared to hematoma location as predictor variables were assessed.
RESULTS: Two hundred and four hypertension ICHs, 55 "probable/definite" CAA-ICHs, and 46 "possible" CAA-ICHs were identified. Despite older age and larger ICH volumes, lower hospital mortality was seen in "probable/definite" CAA-ICH versus hypertension ICH (OR 0.2; 95% CI 0.05-0.8; p = 0.02) after adjusting for female gender, components of ICH score, and EVD placement. There were no mortality differences between "possible" CAA-ICH and hypertension ICH. However, lower hospital mortality was seen in "probable/definite" versus "possible" CAA-ICH (OR 0.2; 95% CI 0.04-0.7; p = 0.02). When using ICH etiology rather than hematoma location, hospital mortality models significantly improved (χ2: [df = 2, N = 305] = 6.2; p = 0.01).
CONCLUSIONS: Further investigation is required to confirm the mortality heterogeneity seen within our primary ICH cohort. Hematoma location may play a role for these findings, but the mortality differences seen among lobar ICH using CAA-ICH subtypes and a failure to identify mortality differences between "possible" CAA-ICH and hypertension ICH suggest the limitations of accounting for hematoma location alone.
参考来源
- Roh D, Sun CH, Schmidt JM, et al. Primary Intracerebral Hemorrhage: A Closer Look at Hypertension and Cerebral Amyloid Angiopathy. Neurocrit Care. 2018. PMID: 29556933. doi:10.1007/s12028-018-0514-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。